Trevi Therapeutics Files 2024 10-K
Ticker: TRVI · Form: 10-K · Filed: Mar 18, 2025 · CIK: 1563880
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
Related Tickers: TRVI
TL;DR
TRVI filed its 2024 10-K. Financials for 2023-2024 detailed.
AI Summary
Trevi Therapeutics, Inc. filed its 2024 10-K on March 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is incorporated in Delaware and headquartered in New Haven, CT. Key financial reporting periods include 2023 and 2024, with specific mentions of fair value measurements and construction in progress.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Trevi Therapeutics' financial performance and operational status for the fiscal year 2024, including details on assets and liabilities.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific financial performance data or forward-looking statements that would indicate a high risk.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the 10-K filing.)
- 2023 — Prior Fiscal Year (Comparative financial data is typically included.)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-18 (date) — Filing date
- New Haven, CT (location) — Company headquarters
- 2023-12-31 (date) — Reporting period
FAQ
What is Trevi Therapeutics, Inc.'s primary business activity?
Trevi Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
When was the 10-K filing submitted to the SEC?
The 10-K filing was submitted to the SEC on March 18, 2025.
What is the fiscal year end for Trevi Therapeutics, Inc.?
The fiscal year end for Trevi Therapeutics, Inc. is December 31.
Where is Trevi Therapeutics, Inc. headquartered?
Trevi Therapeutics, Inc. is headquartered in New Haven, CT.
What specific financial statement items are mentioned in the filing header?
The filing header mentions items such as Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss, Fair Value Measurements Recurring, Construction In Progress, and Retained Earnings.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 18, 2025 regarding Trevi Therapeutics, Inc. (TRVI).